UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference

PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will present at the TD Cowen 46th Annual Health Care Conference to take place March 2-4, 2026.

GlobeNewsWire • 5 hours ago

UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026

PRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

GlobeNewsWire • Feb 23, 2026

UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit

PRINCETON, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit to take place on February 11-12, 2026.

GlobeNewsWire • Feb 4, 2026

Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy

PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

GlobeNewsWire • Jan 5, 2026

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally

New York City-based Wildcat Capital Management sold 495,606 shares of UroGen Pharma in the third quarter. The shares were worth an estimated $6.79 million.

The Motley Fool • Dec 26, 2025

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 14 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto ® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin) for intravesical solution, UroGen's only approved products, and the continued development of UroGen's pipeline.

GlobeNewsWire • Dec 5, 2025

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the Piper Sandler 37th Annual Healthcare Conference to take place on December 2-4, 2025.

GlobeNewsWire • Nov 25, 2025

UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates

UroGen Pharma (URGN) is rated a Strong Buy, with a $33/share price target by end of 2026, driven by its proprietary RTGel technology. URGN's newly approved Zusduri targets a large bladder cancer market, offering a non-surgical alternative, with strong clinical results and significant revenue potential. Jelmyto's commercial success in a smaller market supports confidence in Zusduri's launch, with analysts projecting URGN to reach profitability by 2027.

Seeking Alpha • Nov 25, 2025

UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript

UroGen Pharma Ltd. ( URGN ) Q3 2025 Earnings Call November 6, 2025 10:00 AM EST Company Participants Vincent Perrone - Senior Director of Investor Relations Elizabeth Barrett - President, CEO & Director Mark Schoenberg - Chief Medical Officer David Lin - Chief Commercial Officer Christopher Degnan - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen, Research Division Paul Jeng - Guggenheim Securities, LLC, Research Division Kelsey Goodwin - Piper Sandler & Co., Research Division Raghuram Selvaraju - H.C.

Seeking Alpha • Nov 7, 2025

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the UTOPIA trial ZUSDURI received unique J-Code (J9282) in October 2025, effective January 1, 2026 ZUSDURI achieved net product revenue of $1.8 million in Q3 2025; October 2025 preliminary demand revenue estimate of $4.5 million reflecting accelerating growth entering Q4 2025 JELMYTO® achieved net product revenue of $25.7 million in Q3 2025, representing YoY underlying demand revenue growth of 13% $127.4 million in cash, cash equivalents and marketable securities as of September 30, 2025 Conference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

GlobeNewsWire • Nov 6, 2025